Advertisement
Advertisement
RNA
Atrium Therapeutics, Inc. Common Stock
13.09
USDSponsored
0.00
+0.03%
Mar 26, 15:59 UTC -4
Closed
After-Market
13.10
+0.01
+0.04%
RNA Earnings Reports
Positive Surprise Ratio
RNA beat 12 of 22 last estimates.
55%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$2.80M
/-$1.28
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
+78.15%
/+42.22%
Atrium Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 03, 2026, RNA reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -1.27 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 3.38 million, with a --% difference.
Looking ahead to Q1 26, 9 analysts forecast an EPS of -1.28 USD, with revenue projected to reach 2.80 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Atrium Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Atrium Therapeutics, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Atrium Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Atrium Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Atrium Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Atrium Therapeutics, Inc. Common Stock is expected to report EPS of -$1.28 and revenue of $2.80M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement